Polina Stepensky
HBI0101 CART(Polina Stepensky)은 Systemic Sclerosis (SSc) 표적 세포·유전자 치료로, Multiple Myeloma, Refractory to Standard Treatment; Multiple Myeloma, Relapsed 영역에서 개발·상용화 중입니다. 작용기전: targeted to B-cell maturation antigen. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 4건의 관련 임상이 등록되어 있습니다. 차별점: novel products in the treatment of high-risk patients.
Systemic Sclerosis (SSc)
Multiple Myeloma, Refractory to Standard Treatment; Multiple Myeloma, Relapsed
Recruiting
CAR-T) cell target molecules, with dual-target treatments under d
viral vector) have importance due to their accessibility and cost-effectiveness
humanized CAR-T (FHVH-T), P-BCMA-ALLO-1, ALLO-715, and anti-BCMA CAR-NK, provide promising treatment options
novel products in the treatment of high-risk patients
targeted to B-cell maturation antigen
Cytokine release syndrome was frequent (14/16) but mostly low grade (grade 3: 3/16, no grade 4/5)
BCMA CART demonstrates acceptable and manageable toxicity in a high
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Polina Stepensky
HBI0101 CART(Polina Stepensky)은 Systemic Sclerosis (SSc) 표적 세포·유전자 치료로, Multiple Myeloma, Refractory to Standard Treatment; Multiple Myeloma, Relapsed 영역에서 개발·상용화 중입니다. 작용기전: targeted to B-cell maturation antigen. Phase 2에서 효능·안전성 신호를 검증 중입니다. ClinicalTrials.gov 기준 4건의 관련 임상이 등록되어 있습니다. 차별점: novel products in the treatment of high-risk patients.
Systemic Sclerosis (SSc)
Multiple Myeloma, Refractory to Standard Treatment; Multiple Myeloma, Relapsed
Recruiting
CAR-T) cell target molecules, with dual-target treatments under d
viral vector) have importance due to their accessibility and cost-effectiveness
humanized CAR-T (FHVH-T), P-BCMA-ALLO-1, ALLO-715, and anti-BCMA CAR-NK, provide promising treatment options
novel products in the treatment of high-risk patients
targeted to B-cell maturation antigen
Cytokine release syndrome was frequent (14/16) but mostly low grade (grade 3: 3/16, no grade 4/5)
BCMA CART demonstrates acceptable and manageable toxicity in a high
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.